Parasites, Hosts and Diseases

"Kobsiri Chalermrut"

Original Articles

Minor liver profile dysfunctions in Plasmodium vivax, P. malariae and P. ovale patients and normalization after treatment: Noppadon Tangpukdee, Vipa Thanachartwet, Srivicha Krudsood, Nutthanej Luplertlop, Karnchana Pornpininworakij, Kobsiri Chalermrut, Sasikarn Phokham, Shigeyuki Kano, Sornchai Looareesuwan, Polrat Wilairatana; Korean J Parasitol 2006;44(4):295-302.
Published online December 20, 2006; DOI: https://doi.org/10.3347/kjp.2006.44.4.295

Abstract
PDF

Liver function tests were performed in 61 vivax, 54 malariae and 15 ovale malaria patients who were admitted to Bangkok Hospital for Tropical Diseases between 2001 and 2004. The
objective
of the study was to evaluate changes in hepatic biochemical indices before and after treatment with artemisinin derivatives. On admission and prior to treatment, hepatic dysfunction was found among the 3 groups. Serum liver function tests and physical examinations were performed weekly during the 28-day follow-up period. Initially elevated serum bilirubin and diminished albumin returned to normal within 2 weeks of treatment. Serum alkaline phosphatase and aminotransferases returned to within normal limits within 3 weeks. We conclude that patients with Plasmodium vivax, P. malariae and P. ovale infections had slightly elevated serum bilirubin, aminotransferase and alkaline phosphatase levels, and hypoalbuminemia. These minor abnormalities returned to normal within a few weeks after treatment with therapies based on artemisinin derivatives.

Citations

Citations to this article as recorded by

The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study
John Woodford, G. Dennis Shanks, Paul Griffin, Stephan Chalon, James S. McCarthy
The American Journal of Tropical Medicine and Hygiene.2018; 98(4): 1113. CrossRef
Liver injury in uncomplicated malaria: an overlooked phenomenon
Brioni R. Moore
EBioMedicine.2018; 37: 15. CrossRef
Quantitative Proteomics Analysis of Plasmodium vivax Induced Alterations in Human Serum during the Acute and Convalescent Phases of Infection
Sandipan Ray, Sandip K. Patel, Apoorva Venkatesh, Gangadhar Chatterjee, Naziya N. Ansari, Nithya J. Gogtay, Urmila M. Thatte, Prajakta Gandhe, Santosh G. Varma, Swati Patankar, Sanjeeva Srivastava
Scientific Reports.2017;[Epub] CrossRef
Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria Transmission
Paul Griffin, Cielo Pasay, Suzanne Elliott, Silvana Sekuloski, Maggy Sikulu, Leon Hugo, David Khoury, Deborah Cromer, Miles Davenport, Jetsumon Sattabongkot, Karen Ivinson, Christian Ockenhouse, James McCarthy, Photini Sinnis
PLOS Neglected Tropical Diseases.2016; 10(12): e0005139. CrossRef
Clinico-pathological studies of Plasmodium falciparum and Plasmodium vivax — malaria in India and Saudi Arabia
Wajihullah Khan, Haytham Zakai, Umm-e-Asma
Acta Parasitologica.2014;[Epub] CrossRef
Association of Heme Oxygenase 1 with the Restoration of Liver Function after Damage in Murine Malaria by Plasmodium yoelii
Sumanta Dey, Somnath Mazumder, Asim Azhar Siddiqui, M. Shameel Iqbal, Chinmoy Banerjee, Souvik Sarkar, Rudranil De, Manish Goyal, Samik Bindu, Uday Bandyopadhyay, J. H. Adams
Infection and Immunity.2014; 82(8): 3113. CrossRef
A STUDY OF CLINICAL PROFILE IN PATIENTS WITH P.VIVAX MALARIA
Apte S., Jain J., Parmar A., Apte A., Sinha U, Chanchlani R
Journal of Evolution of Medical and Dental Sciences.2014; 03(03): 575. CrossRef
Mice lacking inducible nitric oxide synthase develop exacerbated hepatic inflammatory responses induced by Plasmodium berghei NK65 infection
Onésia Cristina Oliveira-Lima, Danielle Bernardes, Mauro Cunha Xavier Pinto, Rosa Maria Esteves Arantes, Juliana Carvalho-Tavares
Microbes and Infection.2013; 15(13): 903. CrossRef
Clinico-laboratory profile of severe Plasmodium vivax malaria in a tertiary care centre in Kolkata
Sayantan Ray, Manjari Saha, Debojyoti Sarkar, Arunansu Talukdar, Amitava Chakraborty
Tropical Parasitology.2013; 3(1): 53. CrossRef
Effect of artesunate based combination therapy with homeopathic medicine china on liver and kidney of Plasmodium berghei infected mice
A. Rajan, U. Bagai, S. Chandel
Journal of Parasitic Diseases.2012;[Epub] CrossRef
A Case of Plasmodium ovale Malaria Imported from West Africa
SeJin Moon, Baek-Nam Kim, Eun-Young Kuak, Tae Hee Han
Laboratory Medicine Online.2012; 2(1): 51. CrossRef
Retrospective analysis of vivax malaria patients presenting to tertiary referral centre of Uttarakhand
Saurabh Srivastava, Sohaib Ahmad, Nadia Shirazi, Sanjiv Kumar Verma, Prashant Puri
Acta Tropica.2011; 117(2): 82. CrossRef
Ictericia y hepatopatía en el paciente con malaria
Ana del Mar Cortina, Alberto Tobón
Infectio.2010; 14(4): 277. CrossRef
Clinical Features of Children Hospitalized with Malaria—A Study from Bikaner, Northwest India
Dhanpat Kumar Kochar, Ashish Das, Shilpi Garg, Sanjay Kumar Kochar, Ghanshyam Singh Sengar, Gajanand Singh Tanwar, Anjana Gupta, Abhishek Kochar, Deepak Pakalapati, Vishal Saxena, Poonam Chand Khatri, Sheetal Middha, Jyoti Acharya
The American Journal of Tropical Medicine and Hygiene.2010; 83(5): 981. CrossRef
Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria
Sue Jean Lee, Rose McGready, Christine Fernandez, Kasia Stepniewska, Moo Koo Paw, Samuel Jacher Viladpai-nguen, Kyaw Lay Thwai, Leopoldo Villegas, Pratap Singhasivanon, Brian M. Greenwood, Nicholas J. White, François Nosten
European Journal of Clinical Pharmacology.2008; 64(10): 987. CrossRef
Bilirubin inhibits Plasmodium falciparum growth through the generation of reactive oxygen species
Sanjay Kumar, Mithu Guha, Vinay Choubey, Pallab Maity, Kumkum Srivastava, Sunil K. Puri, Uday Bandyopadhyay
Free Radical Biology and Medicine.2008; 44(4): 602. CrossRef

8,392 View
132 Download
Crossref

Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmodium vivax malaria in Thailand: Srivicha Krudsood, Polrat Wilairatana, Noppadon Tangpukdee, Kobsiri Chalermrut, Siripun Srivilairit, Vipa Thanachartwet, Sant Muangnoicharoen, Natthanej Luplertlop, Gary M. Brittenham, Sornchai Looareesuwan; Korean J Parasitol 2006;44(3):221-228.
Published online September 20, 2006; DOI: https://doi.org/10.3347/kjp.2006.44.3.221

Abstract
PDF

We conducted a study to compare the safety and tolerability of anti-relapse drugs elubaquine and primaquine against Plasmodium vivax malaria. After standard therapy with chloroquine, 30 mg/kg given over 3 days, 141 patients with P. vivax infection were randomized to receive primaquine or elubaquine. The 2 treatment regimens were primaquine 30 mg once daily for 7 days (group A, n = 71), and elubaquine 25 mg once daily for 7 days (group B, n = 70). All patients cleared parasitemia within 7 days after chloroquine treatment. Among patients treated with primaquine, one patient relapsed on day 26; no relapse occurred with elubaquine treatement. Both drugs were well tolerated. Adverse effects occurred only in patients with G6PD deficiency who were treated with primaquine (group A, n = 4), whose mean hematocrit fell significantly on days 7, 8 and 9 (P = 0.015, 0.027, and 0.048, respectively). No significant change in hematocrit was observed in patients with G6PD deficiency who were treated with elubaquine (group B, n = 3) or in patients with normal G6PD. In conclusion, elubaquine, as anti-relapse therapy for P. vivax malaria, was as safe and well tolerated as primaquine and did not cause clinically significant hemolysis.

Citations

Citations to this article as recorded by

Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency
Huaie Liu, Weilin Zeng, Pallavi Malla, Chengqi Wang, Seetha Lakshmi, Kami Kim, Lynette Menezes, Zhaoqing Yang, Liwang Cui
Infection.2023; 51(1): 213. CrossRef
Plasmodium cynomolgi in humans: current knowledge and future directions of an emerging zoonotic malaria parasite
Loick P. Kojom Foko, Amit Kumar, Joseph Hawadak, Vineeta Singh
Infection.2023; 51(3): 623. CrossRef
The medication for pneumocystis pneumonia with glucose-6-phosphate dehydrogenase deficiency patients
Ziyu Zhang, Qinhui Li, Xiaoyan Shen, Lankai Liao, Xia Wang, Min Song, Xi Zheng, Yulian Zhu, Yong Yang
Frontiers in Pharmacology.2022;[Epub] CrossRef
G6PD Variants and Haemolytic Sensitivity to Primaquine and Other Drugs
Germana Bancone, Cindy S. Chu
Frontiers in Pharmacology.2021;[Epub] CrossRef
Targeting Gametocytes of the Malaria Parasite Plasmodium falciparum in a Functional Genomics Era: Next Steps
Jyotsna Chawla, Jenna Oberstaller, John H. Adams
Pathogens.2021; 10(3): 346. CrossRef
Recent Advances in Transmission-Blocking Drugs for Malaria Elimination
Ishan Wadi, Mahendra Nath, Anupkumar R Anvikar, Pargat Singh, Abhinav Sinha
Future Medicinal Chemistry.2019; 11(23): 3047. CrossRef
G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients
Sara Avalos, Rosa E. Mejia, Engels Banegas, Cesar Salinas, Lester Gutierrez, Marcela Fajardo, Suzeth Galo, Alejandra Pinto, Angel Mejia, Gustavo Fontecha
Malaria Journal.2018;[Epub] CrossRef
A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications
Hazem Elewa, Kyle John Wilby
European Journal of Drug Metabolism and Pharmacokinetics.2017; 42(5): 745. CrossRef
Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies
Olalekan A. Uthman, Patricia M. Graves, Rachel Saunders, Hellen Gelband, Marty Richardson, Paul Garner
Malaria Journal.2017;[Epub] CrossRef
Systematic review of the clinical manifestations of glucose-6-phosphate dehydrogenase deficiency in the Greater Mekong Subregion: implications for malaria elimination and beyond
Ken Ing Cherng Ong, Hodaka Kosugi, Sophea Thoeun, Hitomi Araki, Moe Moe Thandar, Moritoshi Iwagami, Bouasy Hongvanthong, Paul T Brey, Shigeyuki Kano, Masamine Jimba
BMJ Global Health.2017; 2(3): e000415. CrossRef
Evaluation of Efficacy of Chloroquine for Plasmodium Vivax Infection Using Parasite Clearance Times: A 10-Year Study and Systematic Review
Hariharan Subramony, Noppadon Tangpukdee, Srivicha Krudsood, Kittiyod Poovorawan, Sant Muangnoicharoen, Polrat Wilairatana
Annals of the Academy of Medicine, Singapore.2016; 45(7): 303. CrossRef
Enantioselective Pharmacokinetics of Primaquine in Healthy Human Volunteers
Babu L Tekwani, Bharathi Avula, Rajnish Sahu, Narayan D Chaurasiya, Shabana I Khan, Surendra Jain, Pius S Fasinu, H.M.T. Bandara Herath, Donald Stanford, N.P. Dhammika Nanayakkara, James D McChesney, Travis W Yates, Mahmoud A ElSohly, Ikhlas A Khan, Larry
Drug Metabolism and Disposition.2015; 43(4): 571. CrossRef
“Recycling” Classical Drugs for Malaria
Cátia Teixeira, Nuno Vale, Bianca Pérez, Ana Gomes, José R. B. Gomes, Paula Gomes
Chemical Reviews.2014; 114(22): 11164. CrossRef
KAI407, a Potent Non-8-Aminoquinoline Compound That Kills Plasmodium cynomolgi Early Dormant Liver Stage ParasitesIn Vitro
Anne-Marie Zeeman, Sandra M. van Amsterdam, Case W. McNamara, Annemarie Voorberg-van der Wel, Els J. Klooster, Alexander van den Berg, Edmond J. Remarque, David M. Plouffe, Geert-Jan van Gemert, Adrian Luty, Robert Sauerwein, Kerstin Gagaring, Rachel Borb
Antimicrobial Agents and Chemotherapy.2014; 58(3): 1586. CrossRef
Novel approaches in antimalarial drug discovery
Jana Held, Andrea Kreidenweiss, Benjamin Mordmüller
Expert Opinion on Drug Discovery.2013; 8(11): 1325. CrossRef
Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine
Gawrie NL Galappaththy, Prathap Tharyan, Richard Kirubakaran
Cochrane Database of Systematic Reviews.2013;[Epub] CrossRef
Effects of Antimalarial Molecules on the Gametocyte Stage of Plasmodium falciparum: The Debate
Odile Dechy-Cabaret, Françoise Benoit-Vical
Journal of Medicinal Chemistry.2012; 55(23): 10328. CrossRef
Targeting the Liver Stage of Malaria Parasites: A Yet Unmet Goal
Tiago Rodrigues, Miguel Prudêncio, Rui Moreira, Maria M. Mota, Francisca Lopes
Journal of Medicinal Chemistry.2012; 55(3): 995. CrossRef
PharmGKB summary
Ellen M. McDonagh, Caroline F. Thorn, José M. Bautista, Ilan Youngster, Russ B. Altman, Teri E. Klein
Pharmacogenetics and Genomics.2012; 22(3): 219. CrossRef
New approaches in antimalarial drug discovery and development: a review
Anna Caroline C Aguiar, Eliana MM da Rocha, Nicolli B de Souza, Tanos CC França, Antoniana U Krettli
Memórias do Instituto Oswaldo Cruz.2012; 107(7): 831. CrossRef
Plasmodium vivax treatments
Ric N. Price, Nicholas M. Douglas, Nicholas M. Anstey, Lorenz von Seidlein
Current Opinion in Infectious Diseases.2011; 24(6): 578. CrossRef
Feeding the Antimalarial Pipeline
Martin Schlitzer, Regina Ortmann
ChemMedChem.2010; 5(11): 1837. CrossRef
Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination
Timothy N.C. Wells, Jeremy N. Burrows, J. Kevin Baird
Trends in Parasitology.2010; 26(3): 145. CrossRef
Blocking Plasmodium falciparum Malaria Transmission with Drugs: The Gametocytocidal and Sporontocidal Properties of Current and Prospective Antimalarials
Anthony E. Kiszewski
Pharmaceuticals.2010; 4(1): 44. CrossRef
Medications and Glucose-6-Phosphate Dehydrogenase Deficiency
Ilan Youngster, Lidia Arcavi, Renata Schechmaster, Yulia Akayzen, Hen Popliski, Janna Shimonov, Svetlana Beig, Matitiahu Berkovitch
Drug Safety.2010; 33(9): 713. CrossRef
A pre-emptive strike against malaria's stealthy hepatic forms
Dominique Mazier, Laurent Rénia, Georges Snounou
Nature Reviews Drug Discovery.2009; 8(11): 854. CrossRef
Resistance to Therapies for Infection byPlasmodium vivax
J. Kevin Baird
Clinical Microbiology Reviews.2009; 22(3): 508. CrossRef
8-Aminoquinolines: future role as antiprotozoal drugs
Babu L Tekwani, Larry A Walker
Current Opinion in Infectious Diseases.2006; 19(6): 623. CrossRef